A commonly prescribed antidepressant can reduce production of the main ingredient in Alzheimer’s brain plaques, according to new research at Washington University School of Medicine in St. Louis and the University of Pennsylvania.
The findings, published Science Translational Medicine
support preliminary studies that evaluated a variety of antidepressants.
The scientists found that the antidepressantåÊ stopped the growth of plaques in a mouse model of Alzheimer’s disease. And in young adults who were cognitively healthy, a single dose of the antidepressant lowered by 37 percent the production of amyloid beta, the primary ingredient in plaques. Amyloid beta is a protein produced by normal brain activity. Levels of this protein rise in the brains of patients with Alzheimer’s, causing it to clump together into plaques. Plaques also are sometimes present in cognitively normal brains. Most antidepressants keep serotonin circulating in the brain, so this researchers to wonder whether the drugs block the increase of amyloid beta levels and slow the progression of Alzheimer’s. In 2011, the researchers tested several antidepressants in young mice genetically altered to develop Alzheimer’s disease as they aged. In these mice, which had not yet developed brain plaques, antidepressants reduced amyloid beta production by an average of 25 percent after 24 hours. In a second experiment, the scientists gave a single dose of citalopram to 23 people ages 18 to 50 who were not cognitively impaired or depressed. Samples of spinal fluid taken from the participants over the next 24 hours showed a 37 percent drop in amyloid beta production. Check with your physician.